Fatigue TOTAL: DAILY Insomnia 0.25 MG Lethargy TOTAL: DAILY: O Medication Error RAL Pyrexia 10.00 MG Sensory Disturbance TOTAL: DAILY: O Serotonin Syndrome RAL Urinary Tract Infection Vomiting White Blood Cell Count Increased Nitrazepam SS ORAL Triazolam SS ORAL and escitalopram.

2. Name of the focal point in WHO supporting the application: Charlie Gilks HIV AIDS Department World Health Organisation.

Drugs that decrease mortality and improve symptoms ACE inhibitors Captopril Capoten ; Enalapril Vasotec ; Lisinopril Zestril ; Ramipril Altace ; Trandolapril Mavik ; 6.25 mg three times daily one-half tablet ; 2.5 mg twice daily 5 mg daily 1.25 mg twice daily 1 mg daily 12.5 to 50 mg three times daily 10 mg twice daily 10 to 20 mg daily 5 mg twice daily 4 mg daily and esomeprazole.

In terms of their sheer addictive powers, the two drugs are identical, study authors say. Tablet 12.5 mg Tablet 25 mg Oral Suspension 12.5 mg 5 ml Oral Suspension 25 mg 5 ml PL 0025 0383 PL 0025 0384 PL 0025 0385 PL 0025 0386 and estrace. Additionally, assessment of the effect of rituximab on quality of life should be undertaken in those centres where the infrastructure exists to support more formal studies of this nature. The Department of Health and the National Assembly.

373 RELATIONSHIP BETWEEN BRAIN STRUCTURAL CHANGES AND PARAMETERS OF CLINIC AND 24H BLOOD PRESSURE IN PATIENTS WITH ESSENTIAL HYPERTENSION O. Gulkevych, E. Svyshchenko, L. Bezrodna, I. Sidorova Kyiv, Ukraine ; 374 RELATIONSHIP BETWEEN IMPAIRMENT OF CEREBRAL BLOOD PERFUSION AND STRUCTURAL CHANGES OF THE BRAIN AT BASELINE AND IN COURSE OF THE TREATMENT WITH INDAPAMIDE OR ENALAPRIL IN HYPERTENSIVE PATIENTS M. Kolodina, V. Mordovin, G. Semke, S. Pekarski, T. Ripp, N. Afanaseva, P. Lukyanenok, I. Efimova Tomsk, Russia ; 375 SILENT CEREBROVASCULAR DISEASE AND COGNITIVE FUNCTION IN ESSENTIAL HYPERTENSION L. Henskens, M. van Boxtel, A. Kroon, P. Hofman, E. Gronenschild, J. Jolles, P. de Leeuw Maastricht, The Netherlands ; 376 RELATIONSHIP BETWEEN PARAMETERS OF 24-H BLOOD PRESSURE AND STRUCTURAL CHANGES OF THE BRAIN IN HYPERTENSIVE PATIENTS G. Semke, V. Mordovin, S. Pekarski, N. Afanasyeva, M. Kolodina, T. Ripp Tomsk, Russia ; 377 EVOKED VISUAL BLOOD FLOW BEFORE AND AFTER DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE - A FTCD STUDY J. Freitas, E. Azevedo, R. Santos, B. Rosengarten * , M. Carvalho Porto, Portugal; * Essen, Germany ; 378 CEREBROVASCULAR AND CEREBRAL PERFUSION RESERVES IN PATIENTS WITH ESSENTIAL HYPERTENSION I. Astanina, T. Ripp, I. Vorozhtsova, I. Efimova Tomsk, Russia ; 379 HYPERTENSION, DIABETES MELLITUS AND SMOKING ON LATTER THROMBOEMBOLIC STROKE IN GREEK POPULATION S. Paximadas, S. Pagoni, X. Tsarouchas, G. Kalokerinos, K. Garefalakis, P. Nikitopoulou Athens, Greece ; 380 EFFECT OF ENOXAPARIN ON BRAIN PERFUSION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION V. Mychka, I. Chazova, K. Mamyrbaeva, V. Gornostaev, V. Sergienko Moscow, Russia ; 381 THE EFFECT OF ORAL LISINOPRIL ON BLOOD PRESSURE LEVELS IN THE ACUTE AND SUB-ACUTE PHASES OF STROKE D.J. Eveson, T.G. Robinson, J.F. Potter Leicester, UK ; 382 INFLUENCE OF PERINDOPRIL MONOTHERAPY ON BLOOD PRESSURE, GLUCOSE AND LIPIDS METABOLISM AND BRAIN PERFUSION IN PATIENTS WITH METABOLIC SYNDROME V. Gornostaev, V. Mychka, V. Sergienko, I. Chazova Moscow, Russia ; 383 HOMOCYSTEINE IN HYPERTENSIVES WITH AN INCREASED MEDIUM-INTIMA CAROTID THICKNESS: IS IT A RISK FACTOR AND A MARKER FOR CEREBRALVASCULAR DISEASES? M. D'Avino, E. De Simone, E. Laurella, N. Bevilacqua, G. Caruso, F. Capasso, D. Caruso Naples, Italy ; 384 PROGNOSTIC VALUE OF AMBULATORY BLOOD-PRESSURE RECORDINGS IN STROKE SURVIVORS WITH TREATED HYPERTENSION G. Tsivgoulis, E. Manios, K. Spengos, J. Spiliopoulou, K. Dolianitis, K. Xynos, P. Tseke, A. Dimitriou, K. Vemmos, N. Zakopoulos, M. Mavrikakis Athens, Greece and estradiol. Sales of our branded pharmaceutical products decreased in 2004 by approximately 12% when expressed in constant currency. An increase in the weighted average value of the Euro, in relation to the U.S. Dollar, had the effect of increasing branded product sales by approximately , 675, 000, resulting in a 4% decrease in branded pharmaceutical sales in the year ended December 31, 2004 when expressed in U.S. Dollars. Branded sales accounted for 25% of total revenues during 2004, compared to 29% of total revenues during 2003. Price reductions that took effect in December 2003 continued to negatively impact our branded product sales during 2004. Most significantly, sales of our branded omeprazole decreased by approximately , 378, 000 from the prior year, as a result of the price reductions, although sales increased 2% during the year in terms of number of units sold. Sales of our branded enalapril, which experienced a 50% increase in unit volume compared to the prior year, increased 22% from the prior year in spite of price cuts, and now accounts for 17% of our branded product sales. Strong sales of our cough and cold medicine, Codeisan, and the launch of our branded version of paroxetine in May 2003 also helped to mitigate the impact of the price reductions. When Euro MP Lord Bethell found he had Parkinson's disease, he was terrified. But here he tells how illness has taught him where there's life, there's hope. Shaky hands, insomnia, a croaky voice, stiffness of the joints, sadness in the face, bleary eyes, grumpiness, stress, depression, a shuffling gait, a lack of synchronisation in swinging the arms - these are just some of the symptoms of a disease that has been my companion and uninvited guest for the past six years. In 1995, when I was 57, my wife Bryony noticed a tremor of my left hand and an occasional twitch of the face muscles. We put it down to stress and hoped it would go away. It became awkward and others began to notice. It was at its worst when I made a speech in the House of Lords, or in what had been my London North-West European Parliament constituency. I had lost it to Labour in the previous year's elections and was struggling to stay afloat politically. At the outset, we thought the tremor might have been brought on by this piece of misfortune, combined with worries about the health of my baby son John, born in August 1995, and the need to build a new career. I was asked by a relative if I might have had a slight stroke. It was time to consult my doctor and it was he who first mentioned the dreaded words 'Parkinson's disease'. It was a bolt from the blue and a dagger in the heart. He sent me to a neurologist, who examined me and on May 9, 1996, wrote: 'When he walks he does not swing his left upper limb as fully as the right. There is a slight facial impassivity with impaired blink frequency. When he elevates his shoulders, the left does not rise as briskly as the right. I told him that I agreed with your provisional diagnosis of early, predominantly left-sided, Parkinson's disease.' It was the beginning of a war that I will have to fight until the end of my days, or until as is constantly predicted ; medical science comes in decisively on my side and destroys the beast. My mother Ann had been a Parkinson's sufferer for the past year. She could hardly walk. But then she was nearly 80 and had contracted many other complaints. It never occurred to me that I was in line for the same disease. Doctors speculate that it may be inherited but nobody yet knows. My first reactions were panic and despair. But I had been led astray by the myth and the stigma. I thought, like many people, that Parkinson's rots the memory and cripples the body in short order. I believed it to be form of Alzheimer's that quickly destroys the mind before rendering the sufferer helpless and then on a slide down to a vegetable state and death, like motor neurone and other fearful brain diseases. I certainly believed that it was the end of my working life, that I had nothing to look forward to but steady deterioration. This is why many people keep to themselves the fact that they have Parkinson's. They sense the double stigma, incurability and involvement with the brain. In fact, more than 120, 000 British people have the disease - a motor disorder characterised by the onset of a rhythmic tremor, muscle rigidity, difficulty in movement and stooped posture. Parkinson's varies greatly. It can cripple its victim quite brutally and swiftly or it can creep up gently and almost without being noticed. But with most of us it can be controlled by medication. Many are still able to work, though usually at a slower pace than before. And there is the hope of a cure in just a very few years and famotidine.

Respiratory infections and overall prescription fell somewhat. Notably, there were declines in the use of Gentamicin, an injectable antibiotic, seldom an evidence-based choice for primary care respiratory infections. However, the choice of antibiotic used over time is of concern because it shows that much of the decrease is from the recommended inexpensive first- line antibiotics Co-trimoxazole and Ampicillin fell from 12.5 percent to 10.2 percent ; . Meanwhile the percentage receiving more expensive Ciprofloxacin remained unchanged. There is worldwide concern regarding resistance patterns to Ciprofloxacin, engendered by its overuse in situations where a first-line antibiotic, or no antibiotic, would be more appropriate. Ciprofloxacin would never be appropriate for this indication, regardless of cost or concerns for resistance. For digestive and intestinal diseases, the antibiotic Metronidazole was the most frequently prescribed medication in both years. Famotidine, a histamine2 receptor blocker H2-blocker ; that reduces gastric acidity and is considered a drug of choice for peptic ulcer disease, was the second most prescribed medication in Year 1--but it dropped off the list in Year 2. Meanwhile, Omeprazole, an effective and powerful but more costly acid inhibitor of the proton pump inhibitor class, doubled in frequency of prescription to become the second most widely used medication during Year 2. This has significant cost implications. Multivitamins, which have no definite efficacy in intestinal disease, were also prescribed frequently. Meanwhile, prescriptions of antacids were very infrequent. It is also of concern that Metronidazole was the most prescribed medication in both years. It has three primary indications in digestive disease: diverticulitis, antibiotic-associated diarrhea, and peptic ulcer disease associated with Helicobacter pylori. However, when used alone for Helicobacter, it has a very low cure rate and promotes development of antibiotic resistance. It is unlikely that these three conditions together represented enough patient visits to support such frequent prescription of Metronidazole. Yet it is often recommended by local gastroenterologists for a wide range of digestive disorders. Domperidone, a relatively expensive antiemetic, doubled in frequency of prescription. While this is a valuable medication, the level of use found in these surveys seems inappropriately high. A pancreatic enzyme combination Festal ; was commonly used both years. This category of medication is very widely used beyond its evidence base. Antispasmotics Drotaverine and others ; were also used, though there is scant evidence of their effectiveness. For genito-urinary diseases, prescription of Ciprofloxacin, an expensive wide spectrum antibiotic, increased from Year 1 to Year 2, while use of Co-trimoxazole Trimethoprim Sulfamethoxazole ; , an inexpensive first line medication for treating urinary infections, decreased between the two time periods14. Nitroxoline, Nitrofurantoin, Furazidine, and Pipemidic acid are reasonable antibacterial selections. The increasing use of Ciprofloxacin and declining use of Trimethoprim Sulfamethoxazole for genito-urinary problems is disturbing, because of the increasing resistance of organisms to Ciprofloxacin worldwide, as a result, in part, of frequent and inappropriate use. Enalapril became the most frequently used medication for genito-urinary disorders in Year 2. It is evidence-based medication for treatment of hypertension and congestive heart failure possibly explaining its appearance at the top of the list of medications for genito-urinary disease which can occur as a complication of hypertension or congestive heart failure. Bipolar disorder: a crippling disease that you should be aware of many people believe that having a perfectly healthy body means that they will be able to live a normal and productive life and fexofenadine. Is limited information available from individual agencies which actually can be linked with other agency data to portray the child victim's route through the criminal justice and juvenile dependency system. Information in the 1998 ICAN Data Analysis Report presents data unique to each agency which may include the type of abuse neglect involved, detailed information on the victim, or the extent of the agency's work. This special report attempts to show the data connections which exist between agencies and information areas which could be expanded. The regular inclusion of this special report was in response to two recommendations presented to the ICAN Policy Committee in the 1990 ICAN Data Analysis Report: 6. All ICAN agencies review their current practices of data collection to ensure that the total number of reports or cases processed by the agencies, irrespective of reason, are submitted in their data reports. 8. ICAN agencies support the data information Sharing Subcommittee efforts to establish guidelines for common denominators for intake, investigations, and dispositional data collection. To implement these recommendations, a team of ICAN Data Information Sharing Subcommittee members, with the benefit of comment from the full Subcommittee, developed and regularly updates the following material: I. List of Child Abuse and Neglect Sections This list of criminal offense code sections identifies relevant child abuse offenses which will permit ICAN agencies to verify and consistently report the offenses which should be considered child abuse offenses, for instance, enalapril and lisinopril.
Vere aortic stenosis AS ; and regurgitation AR ; . There are no recent large studies evaluating the clinical predictors of 30 days mortality in patients pts ; undergoing AVR. Methods: Between 1999-2004, AVR was preformed at St ancis Hospital in 1202 pts mean age 74 9 years, 46% males ; for AS and in 341 pts mean age 67 13 years, 25% males ; for AR, both procedures coronary artery bypass surgery CABG ; . The medical records were reviewed and the 30-days mortality was recorded. Results: By univariate Kendall correlation analysis, compared to AR group, AS pts were older, there were more males, had less prior cardiac surgery, and had more congestive heart failure CHF ; and diabetes in the past. The 30 days mortality was 5.1% in AS group 62 pts ; and 4.4% 15 pts ; in the AR group p .40 ; . In the AS group, the variables predicting 30 days mortality by multivariate logistic regression analysis adjusted for age, gender, and a number of preadmission variables are illustrated in the table. In the AR group, only preadmission CHF predicted death at 30 days OR 4.1, 95% CI, 1.2, 13.6, p-value .02 and pseudoephedrine. Post-decision prices; actual price may vary slightly due to MTF-specific Prime Vendor discounts and or fees MTFs are prohibited from entering into any incentive pricing agreements in any form with PPI pharmaceutical manufacturers to receive additional discounts. System costs are the average weighted daily cost across all 3 points of service MTF, Retail Network, TMOP.

And female 64% decrease; P 0.05 ; nnee mice to a level similar to that in NNee animals see below ; Figure 2, a and b ; . ANOVA analysis in nnee animals confirmed the significant effect of sex P 0.0001 ; and of drug treatment P 0.005 ; on lesion size in Apoe mice, but there was no interaction between sex and drug. The distribution and histological characteristics of plaques in nnee mice treated with enalapril were not different from those in NNee mice. In comparable experiments with NNee mice, enalapril had no effect on either BP or atherosclerotic lesion size. ANOVA analysis showed a significant effect of sex on lesion size P 0.01 ; , but the effect of drug treatment was not significant P 0.47; Figure 2, a and b ; . Relationship between BP and lesion size. To investigate the overall relationship between BP and lesion size, we com and finasteride.
1 year before PDL & 5 months after Captopril, Enalapril and Lisinopril were added to the PDL and Mavik and Lotensin were dropped Time Periods 1 & 3 ; ACEI Use in ACEI Use in Time Period Time Period 3 1 2 ACEI preferred preferred non-preferred non-preferred Per Member Per Month ACEI Costs * Pre ##TEXT## Post Per Member Per Month CV-Medical Costs * Pre 8 1 5 Post 9 5 7 8 Per Member Per Month Number of CV-ER Visits * Pre 0.009 0.000 0.015 0.032 Post 0.017 0.011 0.000 0.014 0.021 Per Member Per Month Number of CV-Hospitalizations * Pre 0.009 0.007 Post 0.013 0.017 0.000 0.011 0.013 Per Member Per Month Number of CV-Office Visits * Pre 0.083 0.132 0.146 Post 0.167 0.156 0.200 Values shown are means for the given time period. T-tests were used to determine p-values. PDL Preferred Drug List * Differences between the pre and post values with p-values less than 0.05 are considered significant and appear in bold text. Editorial activities Journal Peer Reviewer 1999-2005 Neurology, Annals of Neurology, Archives of Neurology, Epilepsia, Epilepsy and Behavior, Epilepsy Research, Drugs, Pediatrics, J. Ophthalmology, CNS Drugs. CLINICAL ACTIVITIES: Certification 1986 National Board of Medical Examiners 1989-present Maryland State License. 1990 American Board of Psychiatry and Neurology: Neurology 1992-2003 American Board of Psychiatry and Neurology: Special Certification in Clinical Neurophysiology ORGANIZATIONAL ACTIVITIES: Societies 1997-1999 Epilepsy Foundation of American: Distinguished Journalism Awards Judge. 2001-present President, Maryland Neurological Society. 2001-present Professional Advisory Board, Epilepsy Association of the Chesapeake Region 2005 Social Security Administration Policy Conference on Neurological Impairments, New York City; Lecture discussant--criteria for disability in epilepsy. Membership American Academy of Neurology American Epilepsy Society American Clinical Neurophysiology Society Eastern EEG Society and flagyl and enalapril, because enalapril diabetes.
VIII. Medical Equipment & other Supplies. Vol. 54 at management of the cough induced by administration of the above mentioned group of substances. The basic condition for the cough to be eliminated by means of the pharmacological intervention, consists of maintaining the primary pharmacological efficacy of ACE-inhibitors, thanks to which they are so widely used in clinical practice. ACE-inhibitors and calcium channel blockers are in combination widely used in the treatment of cardiovascular diseases. This co-administration exhibits synergic hemodynamic, antiproliferative, antithrombotic and antiatherogenic effects Ruschitzka et al. 1998 ; . In our experimental conditions, the animals treated for 15 days with enalapril showed a statistically significant increase of the cough response to mechanical stimuli. Simultaneous administration of enalapril with diltiazem decreased the number of cough efforts in comparison to enalapril monotherapy. A significant decline was found mainly in the tracheobronchial region. The neural pathway responsible for the cough regulation may undergo disease-related changes plasticity ; , which cause that the protective aspects of the cough reflex are replaced by exaggerated and inappropriate coughing in response to stimuli that are otherwise only slightly irritating Mazzone and Canning 2002 ; . Increased incidence of the cough after enalapril treatment is linked with ACE-inhibition and accumulation of bradykinin, substance P, prostaglandins and other pro-inflammatory mediators in the airways Gajdos et al. 2000 ; . These accumulated substances may sensitize airway afferent nerve endings, thereby lowering their chemical and mechanical threshold for activation. From the point of view of afferent nerve endings, the cough reflex is induced by stimulation of rapidly adapting airway mechanoreceptors RARs ; Hargreaves et al. 1992 ; , bronchopulmonary C-fibres Fox 1996 ; and A nociceptors Undem et al. 2002 ; . While all these three types of receptors are activated differently by tussigenic agents, RARs cause a cough directly, C-fibre receptors by local release of tachykinins that stimulate RARs. The reflex role of A nociceptors is not known Widdicombe 2001 ; . Peripheral afferent nerve sensitization may lead to increased input to the nucleus tractus solitarius nTS ; in the brainstem and contribute to the cough plasticity Mazzone and Canning 2002 ; . The mechanism of diltiazem action in suppression of the cough induced by enalapril administration is unknown. Modulation of the cough reflex with diltiazem could involve the peripheral and central level. The antitussive effect of diltiazem can be and fluconazole.

Be-Tabs Prednisone 5mg; Ipvent 400ug MDI; RolabTheophylline 200, 300mg; Venteze 100ug MDI complete, refill. Angitrate 20mg; Carloc 12.5, 25mg; Coversyl; Coversyl Plus; Enalapril Maleate 10, 20mg Cipla Hexal-lisinopril 5, 10, 20mg; Hexazide 25mg; Pharmapress 10, 20mg; Pharmapress Co; Plenish K 600mg; Preterax 2mg; Prinivil 5, 10, 20mg; Puresis 40mg; Purgoxin 0, 25 mg; Ridaq 25mg; Rolab-hydralazine 25, 50mg; Spiractin 25mg Angitrate 20mg; Be-Tabs Aspirin 300mg; Carloc 12.5, 25mg; Coversyl; Coversyl Plus; Enalapril Maleate 10, 20mg Cipla Hexal-Lisinopril 5, 10, 20mg; Hexazide 25mg; Pharmapress 10, 20mg; Plenish K 600mg; Preterax 2mg; Prinivil 5, 10, 20mg; Puresis 40mg; Purgoxin 0, 25mg; Ridaq 25mg; Rolab-hydralazine 25, 50mg; Spiractin 25mg; Warfarin Be-Tabs Prednisone 5mg; Ipvent 40ug; MDI RolabTheophylline 200, 300mg; Venteze 100ug MDI complete, refill. If you forget to take your medicine at any time, take it as soon as you remember provided this is within one hour of your last meal, then continue to take it at the usual times.

42 available donors. With this new preservation method that includes an oxygenated perfluorocarbon solution, you can now use most of these donors for transplant. Our islet trial is the first to show that that these organs from older donors can be successfully utilized, proving direct efficacy in expanding the organ pool for clinical use. Q: Are researchers working on alternatives to immunosuppressive drugs that can pose significant side effects? A: The currently available combination of immunosuppressive drugs has demonstrated efficacy, but these drugs are also very powerful and pose many complications. We are working on alternative strategies to develop safer, more benign immunomodulatory regimens. The long-term goal is the development of islet cell transplantation strategies that will not require continuous antirejection treatment of transplant recipients. Q: Could you tell us about your lab's efforts to establish better transplant tolerance? A: We now have pilot trials to infuse donor-derived progenitor cells from the bone marrow of the donor, called CD34 positive cells, to try to introduce chimerism and donor-specific tolerance to islets from the same donor of the bone-marrow cells. Chimerism is the coexistence of donor and recipient cells in the same body. Q: What are the principal hurdles that you and others face with islet cell transplant? A: There are several obstacles to overcome. First the requirement for immunosuppression limits this procedure to individuals with the most advanced cases of diabetes, in which the disease is very difficult to control. This group would include, for example, patients with hypoglycemic unawareness or patients who continue to have frequent highs and lows in their blood sugars despite appropriate treatment. Only in cases such as these, patients with advanced disease, is the lifelong exposure to antirejection drugs a justified risk. If we develop safer and better immunosuppressive agents to achieve tolerance, the procedure can be opened up to include all patients with diabetes. At that point, the major hurdle will become the lack of availability of human donor pancreases. Even if we can double the current rate of organ donation, we would be able to treat less than one percent of all patients with diabetes. That is why there is a dramatic need for stem cell research, because we need to develop unlimited sources of insulinproducing tissue. Human organ donation alone will not be enough. Q: The use of stem cells remains controversial. Is this the next step, in your opinion? A: There is huge controversy, but yes, this is the next step. In my opinion, embryonic stem cells are to be used like any other donor tissue when doing an organ transplant. If someone needs a heart or liver transplant, you do not say, "We are not going to use this heart to save this child because the donor committed suicide. We don't want to use the organ from this because we don't want to support suicide." Or "because he or she was a victim of drunk driving, we don't want to use the organs from victims of drunk drivers." We don't enter the debate on whether in vitro fertilization should be banned or not, once in vitro fertilization is an accepted medical procedure in the United States. Discarding embryonic cells in the trash and not using them to develop treatments that would help millions of dying people in the United States is, I think, equally as criminal as throwing a heart away in the trash when someone else is dying of heart failure and could benefit from that organ. Q: If we did develop adequate supplies of cells and had the necessary drugs to achieve tolerance, are we nearing a cure or treatment for a chronic problem in diabetes 1 and 2? A: Without developing embryonic stem cells, islet transplantation would be a cure if it works without antirejection drugs--meaning that you have re-educated the immune system against the autoimmune disease diabetes type 1 ; . Islets are no longer destroyed, and you prevent the development of complications. If it's only based on islet transplantation, it would be a cure, but one accessible only to a minority of patients. If we go develop unlimited sources of islet cells, that would be a cure for many more. With an unlimited source of islet cells, you, for example, enalapril diketopiperazine. P 0.003 versus moxonidine hydrochlorothiazide * p 0.001 versus moxonidine hydrochlorothiazide; p 0.039 versus moxonidine enalapril * p 0.001 versus moxonidine hydrochlorothiazide and escitalopram.